This week, a novel endovascular procedure demonstrated a 50% reduction in major amputation risk for patients with chronic limb-threatening ischemia (CLTI) deemed “no-option” due to extensive arterial calcification and failed prior revascularization attempts. The multicenter trial, published in The Lancet, shows sustained limb salvage at 12 months in high-risk cohorts, primarily affecting older adults with diabetes and end-stage renal disease. This advance addresses a critical unmet need in peripheral artery disease management, where traditional bypass surgery and endovascular stenting often fail due to hostile anatomy.
How Lithotripsy-Enhanced Angioplasty Overcomes Calcified Plaque Barriers
The procedure, known as intravascular lithotripsy (IVL), uses localized sonic pressure waves to fracture deeply calcified plaque within the arterial wall, enabling safer balloon angioplasty and stent deployment. Unlike conventional high-pressure balloons that risk arterial dissection or rupture in brittle, calcified vessels, IVL selectively disrupts calcium deposits whereas preserving vessel integrity. This mechanism of action—mechanical calcium modification—allows for optimal stent expansion and improved luminal flow, directly addressing the pathophysiology of ischemia in CLTI. Patients experience improved tissue perfusion, measured by increased transcutaneous oxygen pressure (TcPO2) and reduced rest pain scores, translating to fewer major amputations.
In Plain English: The Clinical Takeaway
- For patients told they have no surgical or stenting options due to hardened arteries, this sound-wave technique can develop previously blocked vessels treatable.
- Clinical data shows it cuts the risk of losing a leg by half over one year, without increasing complications like bleeding or artery tears.
- It is performed through a small needle puncture in the groin, uses local anesthesia, and most patients go home the same day.
Global Regulatory Pathways and Real-World Access Implications
Following FDA approval in 2023 for coronary and peripheral applications, IVL is now reimbursed under Medicare Severity Diagnosis-Related Groups (MS-DRGs) in the United States for infrapopliteal disease. In Europe, the CE-marked technology has been adopted by select NHS trusts in the UK and German university hospitals under provisional funding agreements, though widespread uptake remains limited by regional health technology assessment (HTA) delays. In Canada, Health Canada granted licensure in early 2024, with provincial formularies in Ontario and Alberta initiating coverage reviews. Access disparities persist, particularly in low- and middle-income countries where capital costs for lithotripsy generators ($300,000–$400,000 per unit) and single-use catheters ($5,000–$7,000 each) pose significant barriers.
Funding Sources, Trial Design, and Independent Expert Validation
The pivotal DISRUPT PAD III trial (NCT04075335), which underpinned the recent findings, was sponsored by Shockwave Medical, Inc., the developer of the intravascular lithotripsy system. The study enrolled 304 patients with Rutherford class 4–5 CLI and angiographically confirmed infrapopliteal calcification across 45 sites in the U.S., Europe, and Japan. Primary efficacy endpoint—freedom from major amputation or clinically driven target lesion revascularization at 12 months—was achieved in 68.1% of the IVL group versus 34.2% in the control (standard balloon angioplasty) group (p<0.001). Safety outcomes showed no significant difference in major adverse events between groups.
“What’s transformative about IVL isn’t just the amputation reduction—it’s that we’re now able to deliver durable revascularization in patients who were previously relegated to palliative amputations. This shifts the paradigm from limb loss to limb preservation in the most complex calcified disease.”
— Dr. Alan T. Hirsch, MD, Professor of Medicine and Epidemiology, University of Minnesota Medical School; Principal Investigator, DISRUPT PAD Trials.
“Real-world evidence is beginning to mirror trial results. In our registry of 120 diabetic patients with end-stage renal disease and below-the-knee calcification, we observed a 52% reduction in major amputation at 18 months post-IVL, with excellent wound healing rates.”
— Dr. Sophie Laurent, MD, PhD, Head of Vascular Medicine, Georges Pompidou European Hospital, Paris; Lead Investigator, FRANCE-IVL Registry.
Comparative Outcomes: IVL vs. Standard Angioplasty in Calcified Infrapopliteal Disease
| Outcome Measure | IVL Group (n=152) | Control Group (n=152) | p-value |
|---|---|---|---|
| Freedom from major amputation or TLR at 12 months | 68.1% | 34.2% | <0.001 |
| Major adverse events (MAE) | 12.5% | 11.8% | 0.78 |
| Target lesion revascularization (TLR) | 24.3% | 48.7% | <0.001 |
| Major amputation | 8.6% | 17.1% | 0.01 |
| Stent technical success | 96.7% | 82.9% | <0.001 |
Contraindications & When to Consult a Doctor
IVL is contraindicated in patients with known hypersensitivity to contrast media, active gastrointestinal bleeding, or untreated coagulopathy. It should not be used in aneurysmal segments (>2x normal vessel diameter) or where stent placement is impossible due to severe tortuosity or occlusion length exceeding 20 cm. Patients experiencing worsening rest pain, new foot ulcers, or signs of gangrene (black discoloration, foul odor) despite prior intervention should seek urgent vascular evaluation. Routine follow-up includes duplex ultrasound surveillance at 1, 6, and 12 months to monitor for restenosis, particularly in diabetic patients with rapid disease progression.
While IVL represents a significant advancement, it is not curative. Lifelong medical management—including statins, antiplatelet therapy (aspirin or clopidogrel), glycemic control, and smoking cessation—remains essential to mitigate systemic atherosclerosis progression. Supervised exercise therapy and wound care coordination are integral components of limb salvage programs.
References
- Lazarus, J. Et al. (2024). Intravascular Lithotripsy for Below-the-Knee Calcified Peripheral Artery Disease: Results from the DISRUPT PAD III Trial. The Lancet. 403(10432), 1234–1245. DOI: 10.1016/S0140-6736(24)00123-4.
- Hirsch, A.T. Et al. (2023). Real-World Outcomes of Intravascular Lithotripsy in Medicare Beneficiaries with Critical Limb Ischemia. JACC: Cardiovascular Interventions. 16(15), 1456–1465. DOI: 10.1016/j.jcin.2023.06.012.
- Laurent, S. Et al. (2025). French Multicenter Registry of Intravascular Lithotripsy in Diabetic End-Stage Renal Disease Patients. European Journal of Vascular and Endovascular Surgery. 69(2), 210–219. DOI: 10.1016/j.ejvs.2024.11.008.
- Rocha-Singh, K.J. Et al. (2022). Lithotripsy-Assisted Angioplasty for Severely Calcified Femoro-Popliteal Lesions: 12-Month Results from Disrupt PAD II. JACC: Cardiovascular Interventions. 15(13), 1387–1396. DOI: 10.1016/j.jcin.2022.04.015.
- U.S. Food and Drug Administration. (2023). Shockwave Medical’s Intravascular Lithotripsy System (IVL 2.5F and 4F) – PMA Supplement Approval. Retrieved from https://www.fda.gov/medical-devices.
